ONCOLOGY REQUISITION FORM
GENETIC ANALYSIS OF SOLID TUMORS

GENOMED
Está nos genes.

PATIENT IDENTIFICATION (Mandatory or label):	
Name:	
F ☐ M ☐	Date of birth:
Identification Number:	
GenoMed use only: label	

REFERRING DOCTOR (Mandatory)
Name:
Hospital/Service:
Telephone::
Do you authorize the report to be sent by e-mail? Yes ☐ No ☐ If yes, please indicate the **institucional e-mail address**: _____

CLINICAL DATA AND DIAGNOSIS: Initial Diagnosis ☐ Relapse / Progressive Disease ☐
(describe therapy, if any)

Informed Consent (to be filled by referring doctor):

I hereby confirm that the patient has provided the written consent to the sample processing for diagnostics and/or scientific research purposes Yes ☐ No ☐

Pathology Service

Pathologist:_____ Direct contact : _____

Hospital: _____

Tumour Tissue – Specimen Details: We ask a pathology report where possible, for correctly interpret test results.

Sample Rejection: Decalcified specimens. Specimens with tumorous tissue

Exam nº:_____ **Resection/Biopsy Date:**_____	**Any other relevant information :** (main contaminants, blood, necrosis or other)
FFPE ☐ Surgical resection ☐ Biopsy ☐ Fine Needle Biopsy ☐ *cell-block* **Other** ☐ Liquid based Cytology (ThinPrep® or similar) ☐ Fresh Frozen Tissue	☐ **Sections** (If tumor cell percentage is lower than 20-30% please use macrodissection to enrich the sample) Macrodissection ☐ Yes ☐ No **% Neoplastic Cells**[a]_____ **Each test has a code that indicates the necessary thickness and quantity of sections** (in multiple requests one tube per thickness is enough) **(1) 6x20 µm** **(2) 10x10 µm** **(3) 3x50 µm** **(4) 5x10 µm** **(5) 5x5 µm** **(6) 10x10 µm** (normal tissue + tumour tissue in separate vials)

a – To proceed with CNVs analysis it is necessary the percentage of neoplastic cells in the sample

Liquid Biopsy (7) Please contact laboratory for instructions

☐ EDTA ☐ Cell-free DNA collection Tube **Time of collection :**_____ **Date:**_____ **Technician:**_____

Contact Persons: Dra. Ana Carla Sousa (assousa@medicina.ulisboa.pt)/ Dra. Sónia Santos (soniasantos@medicina.ulisboa.pt) Ext. 47301

GenoMed, Diagnósticos de Medicina Molecular SA
Instituto de Medicina Molecular
Faculdade de Medicina da Universidade de Lisboa

Edifício Egas Moniz
Av. Prof. Egas Moniz
1649-028 LISBOA
PORTUGAL

Tel: (351) 21 799 95 01
Fax: (351) 21 799 95 00
E-mail: genomed@genomed.pt
www.genomed.pt

ONCOLOGY REQUISITION FORM
GENETIC ANALYSIS OF SOLID TUMORS

GENOMED
Está nos genes.

Available Tests by disease

Lung Cancer

Lung ***Standard*** by NGS (1)

Mutations (*Hotspots*): *ALK; BRAF*; *EGFR*; *HER2*; *KRAS*; *MET*
Fusion drivers: *ALK*; *MET* (*skipping* exão 14); *NTRK1*; *NTRK2*; *NTRK3; ROS1*; *RET*
CNVs[a]: *EGFR*; *HER2*; *KRAS*; *MET*

☐ 34900

Lung ***Extended*** by NGS (1)

Mutations (*Hotspots*): *AKT1; ALK; BRAF*; *DDR2*; *EGFR*; *FGFR2*; *FGFR3*; *HER2*; *HER3*; *HER4*; *KRAS*; *MAP2K1*; *MET; NRAS; PIK3CA; RET; ROS1*
Fusion drivers: *ALK*; *FGFR1*; *FGFR2*; *FGFR3*; *MET* (*skipping* exão 14); *NTRK1*; *NTRK2*; *NTRK3; ROS1*; *RET*
CNVs[a]: *EGFR*; *FGFR1; HER2*; *KRAS*; *MET*

☐ 34900

a – To proceed with CNVs analysis it is necessary the percentage of neoplastic cells in the sample

EGFR (exons 18 to 21) (2)	☐ 36063	***MET*** (exon 14 *skipping*) (2)	☐ 34900
BRAF (Val600) (2)	☐ 36314		
KRAS (codons 12, 13 e 61) (2)	☐ 36058	**Resistance Mutation**	
ALK (2p23) rearrangements by FISH (3)	☐ 31710	**p.Thr790Met** in liquid biopsy (7)	☐ 34900
ROS1 (6q22) rearrangements by FISH (3)	☐ 31710	**p.Thr790Met** in tissue rebiopsy (4)	☐ 34900

Colorectal Cancer

RAS (***KRAS/NRAS***)/ ***BRAF*** (Val600) – tumour tissue (4)	☐ 34900	***BRAF*** (Val600) - tumour tissue (2)	☐ 36314
RAS (***KRAS/NRAS***)/ ***BRAF*** (Val600) – liquid biopsy (7)	☐ 34900	**MSI** - Microsatelite Instability (6)	☐ 34650

Brain Cancer

BRAF (Val600) (2)	☐ 36314	**1p36** and **19q13** deletions by FISH (3)	☐ 2x31710
H3F3A (K27M e G34R/V) (2)	☐ 34900	***RELA* (11q13)** rearrangements by FISH (3)	☐ 31710
HIST1H3B (K27M) (2)	☐ 34900	***EGFR* (7p12)** amplification by FISH (3)	☐ 31710
IDH1 (exon 4) (2)	☐ 34900	***PTEN* (10q23.31)** deletion by FISH (3)	☐ 31710
IDH2 (exon 4) (2)	☐ 34900	***BRAF* (7q34)** rearrangements by FISH (3) (BRAF-KIAA1549 fusion and variants)	☐ 31710
TERT gene promoter mutations (C228T and C250T) (2)	☐ 34900		
MGMT Promotor Methylation Detection (2)	☐ 36312		

Melanoma		Tumores do Estroma Gastrointestinal (GIST)	
BRAF (Val600) (2)	☐ 36314	***c-KIT*** (exons 9 and 11) (2)	☐ 2x34847
c-KIT (exon 11) (2)	☐ 34847	***c-KIT*** (exons 9, 11, 13, 14 and 17) (2)	☐ 5x34847
NRAS (codões 12, 13 e 61) (2)	☐ 34900	***PDGFRα*** (exons 12, 14 and 18) (2)	☐ 34900

Available Tests

Her-2/neu amplification by FISH (3) ☐ 31710

MSI - Microsatelite Instability (6) ☐ 34650

PIK3CA in tumour (5) ☐ 34900

BRCA1 e ***BRCA2*** by NGS – tumour tissue (2) ☐ 34900

Biomarkers panel for Solid Tumors by NGS (1) ☐ 34900

Mutations (*Hotspots - 35 genes*): *AKT1; ALK; AR; BRAF; CDK4; CTNNB1; DDR2; EGFR; ERBB2 (HER2); ERBB3 (HER3); ERBB4 (HER4); ESR1; FGFR2; FGFR3; GNA11; GNAQ; HRAS; IDH1; IDH2; JAK1; JAK2; JAK3; KIT; KRAS; MAP2K1 (MEK1); MAP2K2 (MEK2); MET; MTOR; NRAS; PDGFRA; PIK3CA; RAF1; RET; ROS1; SMO*
CNVs[a] (19 genes): *AKT1; ALK; AR; BRAF; CCND1; CDK4; CDK6; EGFR; ERBB2 (HER2); FGFR1; FGFR2; FGFR3; FGFR4; KIT; KRAS; MET; MYC; MYCN; PDGFRA; PIK3CA*
Fusion drivers (23 genes): *ABL1; AKT3; ALK; AXL; BRAF; EGFR; ERBB2 (HER2); ERG; ETV1; ETV4; ETV5; FGFR1; FGFR2; FGFR3; MET; NTRK1; NTRK2; NTRK3; PDGFRA; PPARG; RAF1; RET; ROS1*
a – To proceed with CNVs analysis it is necessary the percentage of neoplastic cells in the sample

Signature of Referring Doctor: _____ **Date:** ____ / ____ / _____

Contact Persons: Dra. Ana Carla Sousa (assousa@medicina.ulisboa.pt)/ Dra. Sónia Santos (soniasantos@medicina.ulisboa.pt) Ext. 47301

GenoMed, Diagnósticos de Medicina Molecular SA
Instituto de Medicina Molecular
Faculdade de Medicina da Universidade de Lisboa

Edifício Egas Moniz
Av. Prof. Egas Moniz
1649-028 LISBOA
PORTUGAL

Tel: (351) 21 799 95 01
Fax: (351) 21 799 95 00
E-mail: genomed@genomed.pt
www.genomed.pt